Sort   by:  
 Page size 
UnknownMM-250: Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in the DREAMM-2 Study: 13-Month Follow-Up
Not available
S-EPMC7832238 | biostudies-literature
UnknownHigh somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.
Not available
S-EPMC5709757 | biostudies-literature
UnknownPharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
Not available
S-EPMC5511594 | biostudies-literature
UnknownAssociation of response endpoints with survival outcomes in multiple myeloma.
Not available
S-EPMC3918869 | biostudies-literature
UnknownMajority of human circulating IgG plasmablasts stop blasting in a cell-free pro-survival culture.
Not available
S-EPMC10864258 | biostudies-literature
UnknownRevised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
Not available
S-EPMC4846284 | biostudies-literature
UnknownSmoldering multiple myeloma current treatment algorithms.
Not available
S-EPMC9445066 | biostudies-literature
UnknownInfluence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.
Not available
S-EPMC5856888 | biostudies-literature
UnknownRelapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
Not available
S-EPMC3563316 | biostudies-literature
UnknownTargeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070.
Not available
S-EPMC2396184 | biostudies-literature
Sort   by:  
 Page size